The cationic lipid, diC14 amidine, extends the adjuvant properties of aluminum salts through a TLR-4- and caspase-1-independent mechanism

Vaccine

Volumn 30, Issue 2, 2012, Pages 414-424

  Wilmar, Arnaud ^a   Lonez, Caroline ^a   Vermeersch, Marjorie ^a   Andrianne, Mathieu ^a   Pérez Morga, David ^a   Ruysschaert, Jean Marie ^a   Vandenbranden, Michel ^a   Leo, Oberdan ^a   Temmerman, Stéphane T ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Adjuvant; Antigen processing; Cationic agent; Cell mediated immunity; Humoral immunity; Innate immunity; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; DIC14 AMIDINE; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOSOME; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL STRUCTURE; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IN VIVO STUDY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; SUSPENSION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; AMIDINES; ANIMALS; CASPASE 1; CELLS, CULTURED; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OVALBUMIN; TOLL-LIKE RECEPTOR 4; VACCINES, SUBUNIT;

EID: 84355162032     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.071     Document Type: Article

References (34)

1. De Gregorio E., Tritto E., Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008, 38:2068-2071.
2. Noe S.M., Green M.A., Hogenesch H., Hem S.L. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010, 28:3588-3594.
3. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001, 69:1151-1159.
4. Sun H., Pollock K.G.J., Brewer J.M. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 2003, 21:849-855.
5. Eisenbarth S.C., Colegio O.R., connor W.O., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
6. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
7. Li H., Willingham S.B., Ting J.P., Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008, 181:17-21.
8. Pétrilli V., Dostert C., Muruve D.A., Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007, 19:615-622.
9. Harris J., Sharp F.A., Lavelle E.C. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur J Immunol 2010, 40:634-638.
10. McKee A.S., Munks M.W., MacLeod M.K.L., Fleenor C.J., Van Rooijen N., Kappler J.W., et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183:4403-4414.
11. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999, 163:6448-6454.
12. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
13. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
14. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
15. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
16. Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants; n.d. http://dx.doi.org/10.1586/Erv.11.17.
17. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173:3148-3154.
18. Tanaka T., Legat A., Adam E., Steuve J., Gatot J., Vandenbranden M., et al. DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur J Immunol 2008, 38:1351-1357.
19. ® Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine 2007, 25:4985-4986.
20. Ruysschaert J.M., El Ouahabi A., Willeaume V., Huez G., Fuks R., Vandenbranden M., et al. A novel cationic amphiphile for transfection of mammalian cells. Biochem Biophys Res Commun 1994, 203:1622-1628.
21. Aksoy E., Zouain C.S., Vanhoutte F., Fontaine J., Pavelka N., Thieblemont N., et al. Double-stranded RNAs from the helminth parasite Schistosoma activate TLR3 in dendritic cells. J Biol Chem 2005, 280:277-283.
22. Maelfait J., Vercammen E., Janssens S., Schotte P., Haegman M., Magez S., et al. Stimulation of Toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. J Exp Med 2008, 205:1967-1973.
23. Li H., Nookala S., Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007, 178:5271-5276.
24. Shi Y., HogenEsch H., Regnier F.E., Hem S.L. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 2001, 19:1747-1752.
25. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 2011.
26. Ng G., Sharma K., Ward S.M., Desrosiers M.D., Stephens L.A., Schoel W.M., et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008, 29:807-818.
27. El Ouahabi A., Thiry M., Pector V., Fuks R., Ruysschaert J.M., Vandenbranden M. The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett 1997, 414:187-192.
28. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2:219-229.
29. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
30. Okemoto K., Kawasaki K., Hanada K., Miura M., Nishijima M. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. J Immunol 2006, 176:1203-1208.
31. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314:1936-1938.
32. Franchi L., Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008, 38:2085-2089.
33. Kool M., Pétrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181:3755-3759.
34. Kool M., Soullié T., van Nimwegen M., Willart M.A.M., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.